» Articles » PMID: 34209172

Molecular Landscape of Vulvar Squamous Cell Carcinoma

Abstract

Vulvar squamous cell carcinoma (VSCC) is a rare malignancy with dual pathogenesis, Human papillomavirus (HPV)-associated and HPV-independent, with a poorly explored molecular landscape. We aimed to summarize the findings of the series analyzing molecular hallmarks of this neoplasm. In January 2021, we conducted a comprehensive literature search using Pubmed Medline and Scopus to identify publications focused on genomic profiling of VSCC. Observational studies, including both prospective and retrospective designs, evaluating molecular alterations in VSCC were deemed eligible. A total of 14 studies analyzing 749 VSCC were identified. The study series were heterogeneous in HPV testing and sequencing strategies, included small sets of tumors and cancer genes, and commonly lacked survival analysis. Only one extensive targeted next-generation sequencing-based study comprised a large cohort of 280 VSCC. The mutated genes, their number, and frequencies were highly variable between the series. Overall, and followed by and were the most frequently studied and mutated genes. Mutations involved in the PI3K/AKT/mTOR pathway, including and have been consistently reported across the studies. However, the role of individual mutations or pathways in the development of VSCC remains unclear. In conclusion, heterogeneity and the small sample size of available molecular series contribute to a limited view of the molecular landscape of VSCC. Large-scale genome- or exome-wide studies with robust HPV testing are necessary to improve the molecular characterization of VSCC.

Citing Articles

The role of HR-HPV integration in the progression of premalignant lesions into different cancer types.

Catalan-Castorena O, Garibay-Cerdenares O, Illades-Aguiar B, Rodriguez-Ruiz H, Zubillaga-Guerrero M, Leyva-Vazquez M Heliyon. 2024; 10(15):e34999.

PMID: 39170128 PMC: 11336306. DOI: 10.1016/j.heliyon.2024.e34999.


Genomic profiles of Japanese patients with vulvar squamous cell carcinoma.

Fujii E, Kato M, Yamaguchi M, Higuchi D, Koyama T, Komatsu M Sci Rep. 2024; 14(1):13058.

PMID: 38844774 PMC: 11156893. DOI: 10.1038/s41598-024-63913-z.


Small biomarkers with massive impacts: PI3K/AKT/mTOR signalling and microRNA crosstalk regulate nasopharyngeal carcinoma.

Li H, Deng N, He X, Li Y Biomark Res. 2022; 10(1):52.

PMID: 35883139 PMC: 9327212. DOI: 10.1186/s40364-022-00397-x.


Advances in Gynecological Cancers.

Liontos M, Fiste O, Zagouri F, Dimopoulos M Int J Mol Sci. 2022; 23(11).

PMID: 35682831 PMC: 9181620. DOI: 10.3390/ijms23116152.


Pathogenesis of Penile Squamous Cell Carcinoma: Molecular Update and Systematic Review.

Ribera-Cortada I, Guerrero-Pineda J, Trias I, Veloza L, Garcia A, Marimon L Int J Mol Sci. 2022; 23(1).

PMID: 35008677 PMC: 8745288. DOI: 10.3390/ijms23010251.


References
1.
Swarts D, Voorham Q, van Splunter A, Wilting S, Sie D, Pronk D . Molecular heterogeneity in human papillomavirus-dependent and -independent vulvar carcinogenesis. Cancer Med. 2018; 7(9):4542-4553. PMC: 6144162. DOI: 10.1002/cam4.1633. View

2.
Vinokurova S, Wentzensen N, Einenkel J, Klaes R, Ziegert C, Melsheimer P . Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst. 2005; 97(24):1816-21. DOI: 10.1093/jnci/dji428. View

3.
Kalu N, Mazumdar T, Peng S, Tong P, Shen L, Wang J . Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Lett. 2018; 431:64-72. DOI: 10.1016/j.canlet.2018.05.029. View

4.
Jenkins T, Mills A . Putative precancerous lesions of vulvar squamous cell carcinoma. Semin Diagn Pathol. 2020; 38(1):27-36. DOI: 10.1053/j.semdp.2020.09.006. View

5.
Zieba S, Chechlinska M, Kowalik A, Kowalewska M . Genes, pathways and vulvar carcinoma - New insights from next-generation sequencing studies. Gynecol Oncol. 2020; 158(2):498-506. DOI: 10.1016/j.ygyno.2020.05.034. View